FDA aprova primeiro tratamento para pericardite recorrente

Referências

1. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF (2021) RHAPSODY Investigators. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 384:31–41

2. FDA.gov. FDA Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-disease-causes-recurrent-inflammation-sac-surrounding-heart. Updated Mar 18, 2021.